Clinical Trial Update: Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis [Phase 2]

View source ↗

Summary

A Phase 2 dose-finding study of AK 3012 in actinic keratosis (Olsen Grade I/II) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• AK 3012

Snippet

Sponsor: Dolorgiet GmbH & Co. KG | Conditions: Actinic Keratosis Olsen Grade I/II | Phase 2 | Status: COMPLETED